Skip to content
Review

Comparative efficacy and safety of first-line therapies for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.

Nov 2026 · Critical reviews in oncology/hematology · pp. 105697 · 0 citations · 59 references
Medicine

Abstract

Background

First-line regimens incorporating immune checkpoint inhibitors (ICIs), adoptive cell therapy (ACT), and targeted agents have expanded treatment options for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma, but their comparative efficacy and safety remain uncertain.

Methods

We searched PubMed, Embase, the Cochrane Library, and major conference proceedings for randomized controlled trials published from 2013 to the prespecified cutoff of August 6, 2025. Frequentist network meta-analysis evaluated overall survival (OS), progression-free survival (PFS), response, disease control, and treatment-related adverse events (TRAEs).

Results

Twenty-nine trials (14,318 patients; 18 treatment nodes) were included. Anti-PD-1 plus doublet chemotherapy improved OS and PFS versus doublet chemotherapy, but heterogeneous PD-L1 criteria precluded CPS-specific inference. ACT plus triplet chemotherapy ranked highest for PFS (P-score, 0.9378) and objective response (SUCRA, 91.1); this node was supported by one 33-patient open-label phase II trial and is hypothesis-generating. PD-1/CTLA-4 and PD-L1/TGF-β bispecific antibodies plus doublet chemotherapy ranked first and second for OS (P-scores, 0.8640 and 0.8624). Missing grade ≥ 3 TRAE data precluded class-wide safety conclusions. Four mixed-site trials included 347 patients with esophageal adenocarcinoma (2.4%). Excluding three abstract-only trials left 15 nodes and broadly similar estimates, although excluded nodes became non-estimable and the PFS effect of triplet versus doublet chemotherapy lost statistical significance.

Conclusions

Within the trial populations represented in this network, anti-PD-1 therapy plus doublet chemotherapy is the best-supported first-line chemoimmunotherapy strategy. The analysis cannot determine CPS-specific effects, and favorable ACT rankings require confirmation before clinical application.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.